Eugenia Kumaga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eugenia Kumaga has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Akihiro Kuno
Laboratory Animal Resource Center in Transborder Medical Research Center, University of Tsukuba, Tsukuba, Japan
1 shared publication Baoshuo Ning
Department of Anatomy and Embryology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
1 shared publication- Eiji Warabi
Department of Anatomy and Embryology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
1 shared publication Hyojung Jeon
Department of Anatomy and Embryology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
1 shared publication- Kei Gochi
Department of Cellular Physiological Chemistry, Institute of Science Tokyo, Tokyo, Japan
1 shared publication - Kunihiro Yamagata
Division of Preventive and Sports Nephrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba , Ibaraki
1 shared publication
Latest Publications
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (9) , 1910-1922
Inhibition of MAFB and PI3K/AKT Signaling for Hereditary FSGS with Multicentric Carpotarsal Osteolysis
Key Points: Multicentric carpotarsal osteolysis, a rare disorder, causes progressive osteolysis and kidney failure because of v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) gene mutations. A genome-edited mouse model carrying the multicentric carpotarsal osteolysis mutation was used to obtain a deeper understanding of this rare disease. Targeting MAFB/IGF-1/PI3K/AKT signaling may provide new treatments for multicentric carpotarsal osteolysis–related nephropathy. Background: Multicentric carpotarsal osteolysis (MCTO) is a rare condition characterized by progressive osteolysis and often kidney failure. It is caused by autosomal dominant mutations in the transcription factor v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B ( MAFB ). Methods: Given the absence of efficacious therapeutic interventions for MCTO and the obscurity of its pathophysiologic mechanisms, we used mice with the MCTO mutation ( Mafb MCTO/MCTO mice) to explore the role of MAFB. Results: Mafb MCTO/MCTO mice displayed FSGS, mirroring the manifestations seen in patients with MCTO. These mice showed that the MCTO mutation leads to the accumulation of MAFB protein. Heterozygous Mafb MCTO/− mice, generated by crossbreeding to reduce MAFB levels, neither exhibited albuminuria nor showed any histologic abnormalities in the kidney, suggesting that excess MAFB was detrimental. We subsequently conducted RNA-seq on the glomeruli from Mafb MCTO/MCTO mice and detected pronounced upregulation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway through IGF-1. Given that receptor tyrosine kinases activate PI3K/AKT, we treated Mafb MCTO/MCTO mice with the inhibitor imatinib. This led to a significant decline in urinary albumin levels compared with the control group. Conclusions: Our findings demonstrate that the MCTO mutation resulted in MAFB protein accumulation and led to the development of FSGS in mice.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (9) , 1910-1922
Inhibition of MAFB and PI3K/AKT Signaling for Hereditary FSGS with Multicentric Carpotarsal Osteolysis
Key Points: Multicentric carpotarsal osteolysis, a rare disorder, causes progressive osteolysis and kidney failure because of v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) gene mutations. A genome-edited mouse model carrying the multicentric carpotarsal osteolysis mutation was used to obtain a deeper understanding of this rare disease. Targeting MAFB/IGF-1/PI3K/AKT signaling may provide new treatments for multicentric carpotarsal osteolysis–related nephropathy. Background: Multicentric carpotarsal osteolysis (MCTO) is a rare condition characterized by progressive osteolysis and often kidney failure. It is caused by autosomal dominant mutations in the transcription factor v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B ( MAFB ). Methods: Given the absence of efficacious therapeutic interventions for MCTO and the obscurity of its pathophysiologic mechanisms, we used mice with the MCTO mutation ( Mafb MCTO/MCTO mice) to explore the role of MAFB. Results: Mafb MCTO/MCTO mice displayed FSGS, mirroring the manifestations seen in patients with MCTO. These mice showed that the MCTO mutation leads to the accumulation of MAFB protein. Heterozygous Mafb MCTO/− mice, generated by crossbreeding to reduce MAFB levels, neither exhibited albuminuria nor showed any histologic abnormalities in the kidney, suggesting that excess MAFB was detrimental. We subsequently conducted RNA-seq on the glomeruli from Mafb MCTO/MCTO mice and detected pronounced upregulation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway through IGF-1. Given that receptor tyrosine kinases activate PI3K/AKT, we treated Mafb MCTO/MCTO mice with the inhibitor imatinib. This led to a significant decline in urinary albumin levels compared with the control group. Conclusions: Our findings demonstrate that the MCTO mutation resulted in MAFB protein accumulation and led to the development of FSGS in mice.